A scoring system to predict life-threatening thromboischemic events in patients with acute promyelocytic leukemia: the PETHEMA/PALG study.


Por: Rodríguez-Veiga R, Gil C, Sobas M, Torres-Miñana L, Botella C, De la Serna J, Bernal T, Salamero O, Otero C, Navarro-Vicente I, De Miguel C, Garrido A, Vives S, Bergua J, Pérez-Encinas M, Algarra L, González-Campos J, Gómez MDMC, Prates MV, Benavente C, Tormo M, Cervera M, Fazio P, Amutio ME, García R, Pomares H, Vidriales B, Serrano J, Amigo ML, Rubio V, Almela Á, Barrios M, Sossa-Melo CL, Paluszewska M, Novo A, Gromek T, Rodríguez-Macías G, Oleksiuk J, Lloret-Madrid P and Montesinos P

Ahead of Print: 13 nov 2025
Resumen:
Acute promyelocytic leukemia (APL) is a highly curable leukemia characterized by life-threatening coagulopathy leading to hemorrhagic and thrombo-ischemic events. We analyzed the incidence, outcomes and risk-factors of thromboischemic events in a large series of 1210 patients with newly diagnosed APL reported to the PETHEMA registry. Therapy consisted on ATRA and chemotherapy (AIDA-based). Median age of patients was 46 years (range 2-90 years). Fifty-eight patients (5%) did not start AIDA regimen as they were unfit for chemotherapy, or they died early before initiating ATRA. A total of 195 (16%) patients developed thrombo-ischemic events, the most frequent being superficial-vein and/or central catheter-related (6.9%) followed by central nervous system (2.2%), deep-vein thrombosis (2.1%), pulmonary embolism (2.1%), acute myocardial infarction (1.6%), or other locations (1.2%). Thromboischemic events mostly occurred at diagnosis and during induction (4.0%, and 9.3%, respectively). Patients developing life-threatening thrombo-ischemic events (i.e, excluding superficial and/or catheter-related) at diagnosis/induction had 31% early death rate. Prolonged aPTT, age >40 years, ECOG more than 1, platelets > 25 x 109/L, and absence of bleeding at presentation were independent risk factors for life-threatening thrombo-ischemic events. Using these variables (1 point each) we developed and validated the Thromb-On risk score, identifying a high-risk group (3 to 5 points). The Thromb-On risk score was validated in a cohort of 585 patients treated since 2017 with arsenic trioxide plus ATRA (<10x109 leukocytes) or AIDA (=10x109 leukocytes). This study could help to improve prevention and management of life-threatening thromboischemic events, through risk-adapted guidance, potentially leading to decrease early mortality in APL.

Filiaciones:
Rodríguez-Veiga R:
 Hematology Department, Hospital Universitari i Politécnic-IIS La Fe, Valencia

Gil C:
 Hematology Department, Hospital General Universitario Dr. Balmis, Alicante

Sobas M:
 Hematology Department, Wroclaw Medical University

Torres-Miñana L:
 Hematology Department, Hospital Universitari i Politécnic-IIS La Fe, Valencia

Botella C:
 Hematology Department, Hospital General Universitario Dr. Balmis, Alicante

De la Serna J:
 Hematology Department, Hospital Universitario 12 de Octubre, CNIO, Complutense University, Madrid

Bernal T:
 Hematology Department, Hospital Universitario Central de Asturias, Instituto Universitario (IUOPA), Instituto de investigación del Principado de Asturias (ISPA), Oviedo

Salamero O:
 University Hospital Vall d'Hebron, and Experimental Hematology, Vall d'Hebron Institute of Oncology, Barcelona

Otero C:
 Hematology Department, Hospital Maciel, Montevideo

Navarro-Vicente I:
 Hematology Department, Hospital Universitari i Politécnic-IIS La Fe, Valencia

De Miguel C:
 Hematology Department, Hospital Puerta de Hierro, Madrid

Garrido A:
 Hematology Department, Hospital de la Sant Creu i Sant Pau, Barcelona

:
 Hematology Department, ICO-Hospital Universitari Germans Trias i Pujol, Institut de recerca Josep Carreras, Badalona

Bergua J:
 Hematology Department, Hospital Universitario San Pedro de Alcántara, Cáceres

Pérez-Encinas M:
 Hematology Department, Hospital Clínico Universitario, Santiago de Compostela

Algarra L:
 Hematology Department, Hospital General Universitario de Albacete, Albacete

González-Campos J:
 Hematology Department, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina (IBIS / CSIC / CIBERONC), Universidad de Sevilla, Sevilla

Gómez MDMC:
 Hematology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria

Prates MV:
 Hematology Department, Hospital Italiano de La Plata (HILP), La Plata

Benavente C:
 Hematology Department, Hospital Clínico San Carlos, Madrid

Tormo M:
 Hematology Department, Hospital Clínico Universitario-INCLIVA, Valencia

Cervera M:
 Hematology Department, Hospital de Tarragona "Joan XXIII"(ICO-Tarragona), Tarragona

Fazio P:
 Hematology Department, Hospital General San Martín, La Plata

Amutio ME:
 Hematology Department, Hospital Universitario Cruces Barakaldo, Bizkaia

García R:
 Hematology Department, Hospital General de Castellón, Castellón

Pomares H:
 Hematology Department, Institut Catala d'Oncologia, Hospitalet del Llobregat

Vidriales B:
 Hematology Department, Hospital Universitario de Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca

Serrano J:
 Hematology Department, IMIBIC, Hematology, Hospital Universitario Reina Sofía, UCO, Córdoba

Amigo ML:
 Hematology Department, Hospital Morales Meseguer, Murcia

Rubio V:
 Hematology Department, Hospital General Jerez de la Frontera, Cadiz

Almela Á:
 Hematology Department, Hospital Universitario de León, León

Barrios M:
 Hematology Department, Hospital Carlos Haya (COMPLEJO HOSPITALARIO REGIONAL DE MÁLAGA), Málaga

Sossa-Melo CL:
 Hematology Department, Fundación Oftalmológica de Santander-FOSCAL Facultad de Ciencias de la Salud, Universidad Autónoma de Bucaramanga-UNAB, Santander, Colombia

Paluszewska M:
 Hematology Department, Medical University of Warsaw, Poland Hematology

Novo A:
 Hematology Department, Hospital Son Espases, Palma de Mallorca

Gromek T:
 Hematology Department, Medical University Lublin (SPSK1), Lublin

Rodríguez-Macías G:
 Hematology Department, Hospital General Universitario Gregorio Marañón, Madrid

Oleksiuk J:
 Hematology Department, Medical University Bialystok, Bialystok

Lloret-Madrid P:
 Hematology Department, Hospital Universitari i Politécnic-IIS La Fe, Valencia

Montesinos P:
 Hematology Department, Hospital Universitari i Politécnic-IIS La Fe, Valencia
ISSN: 03906078





HAEMATOLOGICA
Editorial
Ferrata Storti Foundation, VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY, Italia
Tipo de documento: Article
Volumen: Número:
Páginas:
ID de PubMed: 41230704

MÉTRICAS